Chief Executive Officer
Mr. Brunel joined Velocity Sciences in 2021 serving as its CEO and on its Board of Directors.
Mr. Brunel was a co-founder, board member, and CEO of Biodesix from 2006 to 2020, a company that develops and commercializes non-invasive blood-based molecular diagnostic tests for oncology. Prior to Biodesix, Mr. Brunel was co-founder and President of SomaLogic, a company creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. He was also the founder and CEO of Unidata, Inc. which merged with Vmark Software to create Ardent Software, Inc., where he served as President and as a board member until its sale to Informix.
He served as CEO of Codestream, Ltd, acquired by Blue Phoenix Solutions, eMotion, Inc., acquired by Corbus (now part of Getty Images), and as the Chairman of Xyleme, Inc. until its sale to Bow River Capital. Additionally, Mr. Brunel is currently Chairman of the board of KromaTid, Anark Corporation, and AmideBio and on the board of HepQuant, and InOn Health.
David has a BS in Chemistry from Colorado State University and MA in International Studies from Denver University.
Chief Financial Officer
Jill Clark has served as Chief Financial Officer at Velocity Sciences since its inception in 2014.
Her extensive financial and operational experience spans multiple sectors including biotechnology and hi-tech. With almost 20 years of experience as the financial leader for companies primarily in early and development stages, Ms. Clark is passionate about start-ups.
She has a proven track record of leading companies from angel rounds through multiple private rounds, having raised more than $140M from private equity and venture funding, to successful exits via IPO and acquisitions of approximately $1B.
Prior to joining Velocity Sciences, Ms. Clark was the Chief Financial Officer for Brandscreen Pte Ltd based in Singapore with offices in Shanghai and Sydney. She began her professional career with the accounting firm of PricewaterhouseCoopers.
Ms. Clark holds a Bachelors of Science in Administrative Management from Clemson University.
Vice President of Business Development
Tony Bartlett joined Velocity Sciences in 2021.
He brings a unique combination of experience combining a decade of lab-based antibody generation, manufacturing scale-up, and diagnostic test development with three decades of customer-facing scientific sales, marketing, and general management.
He has a passion for translating cutting-edge technologies through co-innovation and demonstration of value in a broad array of use case settings, particularly where unmet needs have been uniquely satisfied. This passion has resulted in exposure to multiple segments spanning biological research, pharmaceutical discovery, and development, diagnostic assays, and imaging.
Notable technology companies for whom Tony has played founding commercial roles include Affymetrix Inc., PamGene International BV, and SomaLogic Inc, whilst advising many others as a consultant.
He has technical qualifications relating to Applied Biology, as well as degrees in Biological Sciences, and Immunology.
Director of Research Chemistry
Jim Heil joined Velocity Sciences in 2014.
He has worked at numerous biotechnology companies including Amgen, Chiron, Gilead Sciences, and SomaLogic. He has a wide variety of knowledge and experience in many aspects of biotechnology.
His career started in the manufacturing of proteins and peptides. He then transitioned into RNA chemistry, surface chemistry, and assay development. His innovations have had significant impacts on enabling proteomics technologies. In addition to his recent proteomics focus, he worked on a team that developed RNA synthesis methods for CRISPR guide RNA that was purchased by Editas Medicine.
Jim has a B.S. from Colorado State University.
Vice President of Process Chemistry
Keith Jarvis recently joined Velocity Sciences in January 2022.
His previous role was Senior Director of Process Chemistry at Editas Medicine where he led a large multifaceted team that was responsible for high throughput small scale guide RNA production, the development of novel chemical modifications to enhance delivery, guide RNA process development and large scale GMP manufacturing.
He has also led other oligonucleotide related process development and production groups at several biotechnology companies including Ribozyme Pharmaceuticals, Sirna Therapeutics, Merck Research Laboratories and miRagen Therapeutics.
He received his Bachelor of Science degree in Chemistry from the University of North Carolina at Chapel Hill and his Master of Science Degree from the University of Colorado at Boulder.
Dan Feldheim, PhD
Vice President of Bioinformatics and Assay Development
Dr. Feldheim has spent his scientific career both in academics as a Professor of Chemistry, most recently at the University of Colorado-Boulder, and with biotech start-up companies.
Dan has worked to develop new nanoparticle electronic sensor platforms and drug delivery systems for use in oncology and infectious disease applications. His innovations have generated five patents and were awarded fellowships by the David and Lucile Packard Foundation and the Arnold and Mabel Beckman Foundation. He was a founder of a W. M. Keck Foundation Center for RNA Chemistry and has helped start three biotech companies.
Dan received his Ph.D. degree from Colorado State University and was a National Science Foundation postdoctoral fellow at Pennsylvania State University.